ArticleCureus2025
Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) frequently presents with overt metastatic spread, portending a negative prognosis. Conventional treatments include chemotherapeutic agents and molecularly targeted and/or immunotherapeutic agents. Most responders to systemic chemotherapy in metastatic disease experience progression shortly after treatment discontinuation and it is very unusual for a patient to continue to manifest ongoing regression of malignant lesions unless treatment is continued. Moreover, responses occur early during therapy, typically within two to four months, and rarely continue beyond that time frame. In this study, we describe a 67-year-old man with stage IV spindle cell cancer (initially diagnosed as NSCLC) who demonstrated ongoing radiographic regression over 20 months after receiving only a single dose of an immune checkpoint inhibitor (ICI) without any additional systemic therapy. Conventional approaches would have continued the ICI and credited any ongoing response to multiple doses. However, this case emphasizes that short exposure to ICI may be sufficient in select circumstances. Given that the five-year survival rate for stage IV non-small cell lung cancer (NSCLC) has historically been below 5%, observing such a durable response highlights the potential for more individualized immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.